261 related articles for article (PubMed ID: 35672531)
1. Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas.
Autry AW; Lafontaine M; Jalbert L; Phillips E; Phillips JJ; Villanueva-Meyer J; Berger MS; Chang SM; Li Y
J Neurooncol; 2022 Aug; 159(1):43-52. PubMed ID: 35672531
[TBL] [Abstract][Full Text] [Related]
2. In Vivo 2-Hydroxyglutarate Monitoring With Edited MR Spectroscopy for the Follow-up of
Di Stefano AL; Nichelli L; Berzero G; Valabregue R; Touat M; Capelle L; Pontoizeau C; Bielle F; Lerond J; Giry M; Villa C; Baussart B; Dehais C; Galanaud D; Baldini C; Savatovsky J; Dhermain F; Deelchand DK; Ottolenghi C; Lehéricy S; Marjańska M; Branzoli F; Sanson M
Neurology; 2023 Jan; 100(1):e94-e106. PubMed ID: 36180241
[TBL] [Abstract][Full Text] [Related]
3. Tissue 2-Hydroxyglutarate and Preoperative Seizures in Patients With Diffuse Gliomas.
Ohno M; Hayashi Y; Aikawa H; Hayashi M; Miyakita Y; Takahashi M; Matsushita Y; Yoshida A; Satomi K; Ichimura K; Hamada A; Narita Y
Neurology; 2021 Nov; 97(21):e2114-e2123. PubMed ID: 34610989
[TBL] [Abstract][Full Text] [Related]
4. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.
Jafari-Khouzani K; Loebel F; Bogner W; Rapalino O; Gonzalez GR; Gerstner E; Chi AS; Batchelor TT; Rosen BR; Unkelbach J; Shih HA; Cahill DP; Andronesi OC
Neuro Oncol; 2016 Nov; 18(11):1569-1578. PubMed ID: 27382115
[TBL] [Abstract][Full Text] [Related]
5. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.
Andronesi OC; Loebel F; Bogner W; Marjańska M; Vander Heiden MG; Iafrate AJ; Dietrich J; Batchelor TT; Gerstner ER; Kaelin WG; Chi AS; Rosen BR; Cahill DP
Clin Cancer Res; 2016 Apr; 22(7):1632-41. PubMed ID: 26534967
[TBL] [Abstract][Full Text] [Related]
6. 2-Hydroxyglutarate magnetic resonance spectroscopy in adult brainstem glioma.
Iwahashi H; Nagashima H; Tanaka K; Uno T; Hashiguchi M; Maeyama M; Somiya Y; Komatsu M; Hirose T; Itoh T; Sasaki R; Sasayama T
J Neurosurg; 2023 Aug; 139(2):355-362. PubMed ID: 36708540
[TBL] [Abstract][Full Text] [Related]
7. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.
Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA
J Neurosurg; 2019 Jan; 132(1):180-187. PubMed ID: 30611146
[TBL] [Abstract][Full Text] [Related]
8. IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas.
Fujita Y; Nunez-Rubiano L; Dono A; Bellman A; Shah M; Rodriguez JC; Putluri V; Kamal AHM; Putluri N; Riascos RF; Zhu JJ; Esquenazi Y; Ballester LY
J Neurooncol; 2022 Sep; 159(2):261-270. PubMed ID: 35816267
[TBL] [Abstract][Full Text] [Related]
9. In vivo MRS measurement of 2-hydroxyglutarate in patient-derived IDH-mutant xenograft mouse models versus glioma patients.
Tiwari V; Mashimo T; An Z; Vemireddy V; Piccirillo S; Askari P; Hulsey KM; Zhang S; de Graaf RA; Patel TR; Pan E; Mickey BE; Maher EA; Bachoo RM; Choi C
Magn Reson Med; 2020 Sep; 84(3):1152-1160. PubMed ID: 32003035
[TBL] [Abstract][Full Text] [Related]
10. Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma.
Choi C; Raisanen JM; Ganji SK; Zhang S; McNeil SS; An Z; Madan A; Hatanpaa KJ; Vemireddy V; Sheppard CA; Oliver D; Hulsey KM; Tiwari V; Mashimo T; Battiste J; Barnett S; Madden CJ; Patel TR; Pan E; Malloy CR; Mickey BE; Bachoo RM; Maher EA
J Clin Oncol; 2016 Nov; 34(33):4030-4039. PubMed ID: 28248126
[TBL] [Abstract][Full Text] [Related]
11. Comparative Value of 2-Hydroxyglutarate-to-Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas.
Suh CH; Kim HS; Park JE; Jung SC; Choi CG; Woo DC; Lee HB; Kim SJ
Radiol Imaging Cancer; 2020 Jul; 2(4):e190083. PubMed ID: 33778723
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
[TBL] [Abstract][Full Text] [Related]
13. Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients.
An Z; Tiwari V; Ganji SK; Baxter J; Levy M; Pinho MC; Pan E; Maher EA; Patel TR; Mickey BE; Choi C
Magn Reson Med; 2018 Apr; 79(4):1851-1861. PubMed ID: 28833542
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
[TBL] [Abstract][Full Text] [Related]
15. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
[TBL] [Abstract][Full Text] [Related]
16. Neurochemical Differences between 1p/19q Codeleted and Noncodeleted IDH-mutant Gliomas by in Vivo MR Spectroscopy.
Branzoli F; Liserre R; Deelchand DK; Poliani PL; Bielle F; Nichelli L; Sanson M; Lehéricy S; Marjańska M
Radiology; 2023 Sep; 308(3):e223255. PubMed ID: 37668523
[TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.
Elkhaled A; Jalbert LE; Phillips JJ; Yoshihara HAI; Parvataneni R; Srinivasan R; Bourne G; Berger MS; Chang SM; Cha S; Nelson SJ
Sci Transl Med; 2012 Jan; 4(116):116ra5. PubMed ID: 22238333
[TBL] [Abstract][Full Text] [Related]
18. Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy.
Natsumeda M; Motohashi K; Igarashi H; Nozawa T; Abe H; Tsukamoto Y; Ogura R; Okada M; Kobayashi T; Aoki H; Takahashi H; Kakita A; Okamoto K; Nakada T; Fujii Y
Neurosurg Rev; 2018 Apr; 41(2):641-647. PubMed ID: 28956184
[TBL] [Abstract][Full Text] [Related]
19. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.
Choi C; Ganji SK; DeBerardinis RJ; Hatanpaa KJ; Rakheja D; Kovacs Z; Yang XL; Mashimo T; Raisanen JM; Marin-Valencia I; Pascual JM; Madden CJ; Mickey BE; Malloy CR; Bachoo RM; Maher EA
Nat Med; 2012 Jan; 18(4):624-9. PubMed ID: 22281806
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma.
Chuntova P; Yamamichi A; Chen T; Narayanaswamy R; Ronseaux S; Hudson C; Tron AE; Hyer ML; Montoya M; Mende AL; Nejo T; Downey KM; Diebold D; Lu M; Nicolay B; Okada H
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35606087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
